We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Aptamer Group Plc | APTA | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.625 | 08:00:16 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.625 | 0.625 | 0.625 | 0.625 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 06/5/2024 07:37 by multibagger Good morning marinelife, timbo003 and all :)I fully agree with you that the potential upside from the various irons in the fire far outweigh the risk of dilution IMHO. The size of upfront payments for gene delivery and aptamer conjugated drug delivery systems is huge and typically seems to several tens of million $. Even if it could be argued that these multi million $ payments were for "products" which were further down the clinical development pathway, it could follow that "proof of concept" products could generate at least single digit million payments be it in diagnostics, specialised reagents or therapeutics ? In a recent online recent presentation relating to Metabolic Associated Steato-Hepatitis (MASH or "fatty liver" - a common liver condition globally that can sometimes progress to cirrhosis and liver failure) on potential drug delivery mechanisms , Dr DB displayed the selective and specific, non-toxic, profile of an APTA optimer targeting diseased "fatty cells" in the liver whilst not binding with healthy liver cells. This to me is the scientific equivalent of a Holy Grail for drug delivery - from a company with a market cap of less than £3 million ! The Boehringer upfront deal with Ochre Bio for what appears a similar technology has been inked at $35m (for investigating a range of targets) and could finally end up around $1.3 Billion ! The APTA founders Dr Arron Tolley and Dr David Bunka have been far, far more diluted than any of us can ever be and I sincerely feel for them. From each owning 50% of a very successful company which was doubling revenues every year till they IPOed at 117p to what they hold now and at the current share price is a travesty. So there will be zero appetite for equity dilution if at all it can be avoided. I hope they buy some shares from the market to instil more confidence in the Company and park them in their ISAs !! I am sure that they and APTA will overcome this unfortunate debacle and reach their former glory, if not exceed it. Good luck all ! |
Posted at 05/5/2024 14:23 by multibagger Many thanks for your kind perspective and rationale....I am not sure if you have seen this APTA webinar from March 2024 The financial and cash position discussion is from about 9m 20sec onwards..... According to this slide the cash position was actually (better) at £2.1 as of 31st Jan 2024. So some revenues are coming in. Another more recent presentation and Andrew Rapson comes in around 13min 23 sec in with regards to finances Different ways to time the entry into a stock. I am not good at getting the timing right, so I am aim for the "sweet 60%"...in other words I don't expect to buy in the lowest 20% of the share price or be able to sell in the highest 20% of the share price APTA is publicly listed and hence the primary reason is to raise capital and I am sanguine about it. The only question I ask is it for "survival" or is it for "growth" and given how fund raises come about, it is often piggybacked to some excellent RNS news which propels the share price in the short term and allows a placing at a higher share price than previous level. At this time though money is tight, we are able to keep the lights on fwith about £1.3m in the labs (in production) and a £2.9m sales pipeline. I accept that a fund raise is likely to happen in the future but not as early as you predict (based on the evidence above), but the way I see it given we are at around 0.68p, any good news of significance can propel this 200+% in the blink of an eye and I don't want to be chasing the buying then. Good luck - we are all in the market to make money, though our thought processes and methods to get there are different. |
Posted at 05/5/2024 10:33 by bones698 Morning lalYes good points the type of clients apta are getting on oars with is very good and why it's on my radar. As you know though these things move very slowly in this sector whether it's contract talks or r and d it'just seems to take an age for things to move forward. While the names are good the contracts are very small for now and apta does have a funding issue coming very soon. There are ways but for the majority thi reuskts in a big discount especially if its left late. At the bed of ye day it's about buying at The lowest point to maximise gains and when you know funding is coming that is likely the low point. Look at sce recently. Different sector but shows the problems with funding Apata told us they will need money soon, not enough contract wind of any size to avoid that so as an investment it makes sense to wait for that before considering buying imo . |
Posted at 05/5/2024 08:07 by multibagger Good morning timbo003 and all !Hope you are having some great weather ! Many thanks for your kind words and warm welcome to your thread and for sharing your career earned insights from big Pharma R&D and Consumer care ! These are priceless to the likes of me :) There was recent news (below) from Boehringer which is very heartening, as we have been told that APTA are also working in this area of MASH..one pharma licensing deal can be absolutely transformational for APTA and there seem to be number of irons in the fire. To me it is not a question of if, but when....that a big RNS lands and the share price could do several hundred % in a short time as we are starting from a very low share price Anyone remember NCYT during the Covid years going from 6p to £12 plus in a very short span of time ? I fully agree with you that though some may view APTA with "suspicion" in terms of need to raise funds in the near future, the funding landscape is changing and evolving. There are other ways in which funds could be raised if needed and the likes of Unilever will not want to lose a "strategic technology edge" to the likes of P&G, L'oreal or Biersdorf. Take for example the recent news from a Japanese pharma consortium looking at an Incubator Fund. From the company power point presentations and logos of partners advertised, I guess we have worked with Takeda in the past and may be doing so currently ? Another company is called Orchard Therapeutics which recently announced breakthrough therapy for an orphan condition MLD and is reputed to being sold at over $4 million per patient per year....precision medicine solutions are very expensive. So IMHO the market is grossly mis-pricing the value of precision medicine therapies in a company like APTA and they seem to be working with top 5, top 10 and top 15 pharmas already. I believe that the upside is potentially huge and will act accordingly ! Good luck all :) |
Posted at 05/5/2024 02:19 by timbo003 Good evening Multibagger (from Palm Springs, Ca), it is good to have you on board.You may be correct in your analysis bones698, but on the other hand this current dire funding environment will not continue indefinitely. My own view is that we are close to the bottom (if not already off the bottom) of the cycle as far as sentiment towards funding this sort of venture is concerned. As and when sentiment improves, investors will need to change their mindset from expecting a lower price for each successive raise to anticipating upwardly ratcheting prices for each fund raise which will more accurately reflect the (increased) value of the business as projects are progressed and more potential customers are taken on board. Aptamer have sufficient cash until the end of the year, so I suspect they will not need to approach potential funders until Q4, that means there are 4+ months to sign up more deals with the likes of Unilever and the top 15 pharma (precision liver medicine deveopment). It is also worth noting that in the case of Unilever, the project has now moved to the next stage. In my experience (25+ years R&D big pharma/Consumer Healthcare) this step normally represents a significant ratchet up in effort and resources by the customer. Aptamer they will now have an internal champion within Unilever and they have now evidently managed to compete successfully against other (in house and external) Unilever pojects to secure internal resource. One other point to consider, many of Apta's current and prospective customers have very deep pockets and many have an established venture funding arm (including Unilever) so do not rule out one (or more) of them taking a strategic stake in Apta at some stage in the not too distant future. |
Posted at 01/5/2024 07:34 by multibagger Good morning porky9 and all :)Many thanks for a very thorough and considered reply with your perspectives- much appreciated ! I have taken a small position relative to some of the TR1 big hitters we have been hearing of late. I have been doing some digging and asking around: the York scientific community is a small one ! You are right that the previous Board was profligate with Other People's Money. The failing expensive BoD was ejected in Aug 2023 and funding secured at deep discount - the two are interconnected I was told. I was very surprised to learn that neither Prof.Dr. Arron Tolley nor Prof.Dr. David Bunka had a partial cash exit at the time of the IPO as is the norm for founders - they have "lost £ millions" rather than actually made money. They have not enriched themselves, but sadly have been victims of the shenanigans/poor advice of the City folk it would appear (from what I gather). It looks like they went from each controlling 50% of the pre-IPO business to their current equity holdings in low single figures at the current share price - I estimate their personal losses from the current situation to be in the £tens of millions each. Rumour has it that one of the founders challenged the post IPO BoD about profligate spending and was "pushed out". From a scientific and business process, APTA can only initiate work when their customers give them the "target of interest" sample to develop an affinity ligand for. Sometimes the customers themselves are unable to provide the sample it would appear or delays occur. So it would follow that work and contract revenues are lumpy and can convey the impression of a business that is sitting around for orders. Not quite from the stream of news that is being put out and Investor presentations. I am intrigued and my appetite has been whetted - I shall try and learn more in the next few weeks but my gut instinct is that the market is punishing APTA for legacy issues that the current BoD had little to do with. I have a background in science so some of their technical briefings are more understandable to me. A single deal can be £££ transformational and their affinity ligand portfolio/suite seems to be very IP rich and I have been doing Patent searches and love what I see. I am a contrarian and an outlier in many ways and invest accordingly and it has worked for me over the last 3 decades or so...so I have cautiously dipped my toe :) Good luck all ! |
Posted at 28/2/2024 10:46 by dannymaz89 AstraZeneca has extended its drug delivery collaboration with #APTA Aptamer Group. The revised deal sets AstraZeneca up to build on research into the use of aptamer molecules to target renal cellsUpdate on this work soonYes that's right #APTA already in bed with Zeneca #RNS |
Posted at 15/12/2023 11:14 by ddonaldson2 Well bigruss when you call news every week yes of course you will be right eventually.... e.g. 3rd of November news next week looolbigruss1 - 03 Nov 2023 - 15:48:16 - 2117 of 4043 ☆☆ Aptamer Group - Novel Antibody Mimetics (Optimers) ☆☆ - APTA News next week could be tbh but I think they have been holding off due to placement shares being flipped personal I think its done I would prefer a slow and steady rise up to news results should be very good imo big deal being worked on with the 300k r&d funding massive multibag company this one buy and just hold i am A few others saying the seller is gone lmao bigruss1 - 01 Dec 2023 - 09:25:33 - 3596 of 4043 ☆☆ Aptamer Group - Novel Antibody Mimetics (Optimers) ☆☆ - APTA totally agree expecting the placement TR1 soon seller will be out still thing there holding off news so we have a clear path to 4p and mates can all get in .so clear if you think about it bigruss1 - 28 Nov 2023 - 10:52:36 - 3152 of 4043 ☆☆ Aptamer Group - Novel Antibody Mimetics (Optimers) ☆☆ - APTA anyone wondered why you can sell a lot of shares but to buy at a premium and not a lot is hard ..guess not because the clowns on here have nothing to invest ..don't have a real trading platform but you clown cant see it or know what's behind closed doors so the day will come and the clowns go back to there circus all dressed as little sad clown with little tears rolling down there little faces while there little pea size brains wondering why the RNS has rerated the company because that's what's going to happen here .and when that day does come soon there will be nothing the clowns 🤡 can do about it..so the last laugh will be all shareholders ..its not what you know but who bigruss1 - 26 Nov 2023 - 12:33:15 - 3064 of 4043 ☆☆ Aptamer Group - Novel Antibody Mimetics (Optimers) ☆☆ - APTA seller was active last week so expect i raise in share price this week and maybe a TR1 ..the company will be working hard to get them opinions for bod and staff first stop 4p |
Posted at 14/12/2023 07:11 by thehitman1 Aptamer Group signs material agreement with genetic medicines company- Optimer binders will be developed to support targeted genetic medicines to specific cell types- Contract comprises up to GBP553k in development fees for Aptamer Group Aptamer Group plc (AIM: APTA), the developer of novel Optimer (R) binders to enable innovation in the life sciences industry, announces that it has entered into a material agreement with a biotechnology company developing genetic medicines .Under the terms of the agreement, Aptamer Group will use its proprietary platform to discover Optimer binders to enable the specific targeting of genetic medicines to specific cell types. Aptamer Group will receive up to GBP553,000 in development fees for discovering and developing the Optimer binders. Work is expected to commence shortly subject to receiving target materials from the customer and is expected to be completed within the current financial year. |
Posted at 19/9/2023 14:40 by tomboyb Aptamer Group PLC Placing and Subscription, PDMR Dealing and TVR (9603M)19/09/2023 2:35pm UK Regulatory (RNS & others) Aptamer (LSE:APTA) Intraday Stock Chart Tuesday 19 September 2023 Click Here for more Aptamer Charts. TIDMAPTA RNS Number : 9603M Aptamer Group PLC 19 September 2023 19 September 2023 Aptamer Group plc ("Aptamer", the "Company" or the "Group") Placing and Subscription to raise GBP310,772 PDMR Dealing Total Voting Rights Aptamer Group plc (AIM: APTA), the developer of novel Optimer (R) binders to enable innovation in the life sciences industry, today announces that it has raised GBP310,772 through the issue of 28,251,956 new Ordinary Shares by way of a subscription and a placing by Turner Pope to certain existing shareholders at 1.1p per share (the "Issue Price") (together, the "Fundraise"). The Fundraise was initiated following approaches from existing non-UK shareholders who could not be contacted in time to participate in the August 2023 fundraise and extended to take advantage of demand from other existing shareholders using the Company's remaining net authorised unissued share capital. The Fundraise includes a subscription by Dr Adam Hargreaves, a non-executive director of the Company, for 5,000,000 new Ordinary Shares for a total investment of GBP55,000. Following this further investment, Dr Hargreaves is now interested in 22,500,000 Ordinary Shares representing 4.81 per cent of the enlarged issued share capital. In addition, an existing investor, Mr Nicholas Slater, is investing GBP50,000 in the Fundraise for 4,545,454 new Ordinary Shares, taking his holding to 26,045,454 Ordinary Shares representing 5.57% of the enlarged issued share capital. The net proceeds will be ringfenced to support research and development (R&D) activities within the business, including the ongoing process improvements. R&D work was reduced as part of the Company's new strategy to support cost-cutting in August. While higher-risk development activities will still aim to be funded by grants, the new funds will enable internal validation of the technology in key focus areas. Total Voting Rights Application for the admission of the new Ordinary Shares to trading on AIM ("Admission") has been made and Admission is expected on Monday, 25 September 2023, following which the total number of shares in issue and total voting rights will be 467,343,673. The Group does not hold any shares in treasury and, therefore, the above figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in the Company. - ENDS - |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
